Check the time stamp on this data. Updated AI-Generated Signals for Viking Therapeutics Inc. (VKTX) available here: VKTX.

Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with ...

On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...

VK2809 found that those on the medicine saw statistically significant reductions in liver fat, meeting the primary endpoint.

Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

There aren't many biotechs that are more exciting than Viking Therapeutics(NASDAQ: VKTX) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics VKTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Did Viking Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VKTX ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...